Valneva SE (EPA:VLA)
France · Delayed Price · Currency is EUR | Market Cap | 509.31M -18.9% |
| Revenue (ttm) | 142.94M -27.2% |
| Net Income | -157.65M |
| EPS | -0.88 |
| Shares Out | 190.26M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 387,888 |
| Open | 2.624 |
| Previous Close | 2.591 |
| Day's Range | 2.602 - 2.684 |
| 52-Week Range | 2.033 - 5.150 |
| Beta | 1.45 |
| Analysts | Buy |
| Price Target | 6.20 (+131.6%) |
| Earnings Date | Nov 24, 2026 |
About Valneva SE
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease ca... [Read more]
Financial Performance
In 2025, Valneva SE's revenue was 174.66 million, an increase of 3.00% compared to the previous year's 169.58 million. Losses were -115.19 million, 840.6% more than in 2024.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for VLA stock is "Buy." The 12-month stock price target is €6.20, which is an increase of 131.60% from the latest price.
News
Valneva Reports Five-Year Antibody Persistence For Chikungunya Vaccine IXCHIQ
(RTTNews) - Valneva (VALN) reported new long-term data showing that 94% of participants maintained a sero response five years after receiving a single dose of its chikungunya vaccine, IXCHIQ.
Valneva Reports Sustained 94% Seroresponse Five Years After a Single Dose of Chikungunya Vaccine IXCHIQ®
Lyon (France), November 10, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported positive five-year antibody persistence data for its single dose chikungu...
Valneva Reports Positive Mid-Stage Results For Shigella Vaccine Candidate S4V2
(RTTNews) - Valneva (VALN) reported positive Phase 2 results for its experimental S4V2 vaccine, a candidate designed to protect against shigellosis, a serious bacterial infection that causes severe di...
Valneva Announces Positive Phase 2 Results for Tetravalent Shigella Vaccine Candidate S4V2
Data from infant immunogenicity and safety trial, and controlled human infection model (CHIM) trial, demonstrate favorable safety profile with encouraging immunogenicity and efficacy signals
Valneva to Report Nine-Month 2026 Consolidated Financial Results on November 24, 2026
Lyon (France), November 4, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it will report its nine-month 2026 financial results on Tuesday, Nov...
Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences
Lyon (France), October 14, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will present and participate in meetings with ...
UK Revokes Marketing Authorisation For Valneva's Chikungunya Vaccine IXCHIQ; Shares Slide
(RTTNews) - Valneva SE (VALN), a speciality vaccine company, announced that after a further benefit-risk assessment of IXCHIQ for travellers by the United Kingdom's (UK) Commission on Human Medicines ...
Valneva announces Ixchiq marketing authorization revoked by UK MHRA
Valneva (VALN) announced that, following a further benefit-risk assessment of Ixchiq for travelers by the United Kingdom’s Commission on Human Medicines, or CHM, the UK marketing authorization for Ixc...
VALNEVA SE: Valneva Provides Update on IXCHIQ in the United Kingdom
Lyon (France), October 07, 2026 - Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that, following a further benefit-risk assessment of IXCHIQ for trave...
Valneva Provides Update on IXCHIQ® in the United Kingdom
Lyon (France), October 07, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that, following a further benefit-risk assessment of IXCHIQ® for traveler...
Pfizer, Valneva announce EMA validation for PF-07307405 MAA
Pfizer (PFE) and Valneva (VALN) announced that the European Medicines Agency, or EMA, has validated the marketing authorization application, or MAA, for PF-07307405, the companies’ 6-valent outer surf...
Valneva Stock (VALN) Soars Over 20% On Lyme Disease Vaccine Hopes
Shares in biotech Valneva ($VALN) soared over 20% in early trading today after it and partner Pfizer ($PFE) as it moved closer to bringing its Lyme disease vaccine to Europe.
Pfizer and Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency
NEW YORK & LYON, France--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that the European Medicines Agency (EMA) has validated the Marketin...
Valneva Q2 Earnings Call Highlights
Valneva NASDAQ: VALN reported lower first-half revenue and wider losses for 2026, while maintaining its full-year sales outlook and emphasizing its cash position, restructuring measures and expectatio...
Valneva SE Earnings Call Transcript: Q2 2026
H1 2026 saw lower revenues and higher losses due to non-recurring costs and restructuring, but cash position improved. Guidance for 2026 is reaffirmed, with financial self-sustainability targeted for 2027, pending Lyme vaccine approval. Pfizer filed for EMA review, and R&D pipeline progress continues.
Valneva SE Earnings release: Q2 2026
Valneva SE released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Valneva SE Slides: Q2 2026
Valneva SE has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 13, 2026.
Valneva SE Earnings release: Q2 2026
Valneva SE released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Valneva SE Quarterly report: Q2 2026
Valneva SE has published its Q2 2026 quarterly earnings report on August 13, 2026.
Valneva Reports Half Year 2026 Financial Results and Provides Corporate Updates
Lyon (France), August 13, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported its condensed consolidated financial results for the first half of the year...
Valneva initiated with a Buy at TD Cowen
TD Cowen initiated coverage of Valneva (VALN) with a Buy rating and $12 price target The company’s base vaccine business offers downside protection, while LB6V is a “de-risked” Lyme disease…
Valneva to Report First Half 2026 Consolidated Financial Results on August 13, 2026
Lyon (France), July 22, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it will report its first half 2026 financial results on Thursday, Augus...
Valneva SE Slides: Company presentation
Valneva SE has posted slides in relation to its latest quarterly earnings report, which was published on July 1, 2026.
Valneva Announces Successful Outcome of its Annual General Meeting
Dr. Gerd Zettlmeissl is appointed as Chair of the Board of Directors Lyon (France), June 25, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that sh...
Valneva files to sell 31.79M ordinary shares for holders
17:06 EDT Valneva (VALN) files to sell 31.79M ordinary shares for holders